Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
0(0%)
Results Posted
120%(12 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_2
2
17%
Ph phase_3
9
75%
Ph phase_4
1
8%

Phase Distribution

0

Early Stage

2

Mid Stage

10

Late Stage

Phase Distribution12 total trials
Phase 2Efficacy & side effects
2(16.7%)
Phase 3Large-scale testing
9(75.0%)
Phase 4Post-market surveillance
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(10)
Terminated(2)

Detailed Status

Completed10
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (16.7%)
Phase 39 (75.0%)
Phase 41 (8.3%)

Trials by Status

completed1083%
terminated217%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_3

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

NCT04029480
terminatedphase_3

Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study

NCT04600921
terminatedphase_4

Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure

NCT04071626
completedphase_3

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

NCT01999218
completedphase_3

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

NCT02630706
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04029480Phase 3

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

Completed
NCT04600921Phase 3

Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study

Terminated
NCT04071626Phase 4

Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure

Terminated
NCT01999218Phase 3

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Completed
NCT02630706Phase 3

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

Completed
NCT01096667Phase 2

Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

Completed
NCT02036515Phase 3

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

Completed
NCT01059825Phase 2

Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

Completed
NCT02099110Phase 3

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

Completed
NCT01986855Phase 3

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

Completed
NCT02033889Phase 3

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

Completed
NCT01958671Phase 3

A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12